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FOREWORD 
 
Individuals or small groups in each District Health Authority in Trent have historically 
considered evidence on the likely effectiveness of new procedures or therapies in 
conjunction with their cost, making judgements on whether these should be supported. 
Since all or most Health Authorities face the same issues, there tends to be repetition in 
analysis and this can be wasteful of scarce professional expertise. 
 
There are national attempts to remedy this situation by providing information on the 
effectiveness of interventions and these are welcomed. There remains, however, a 
significant gap between the results of research undertaken and their incorporation into 
contracts.  
 
Following a request from purchasers, a network has been established in the Trent Region to 
allow purchasers to share research knowledge about the effectiveness of acute service 
interventions and to determine collectively their purchasing stance. 
 
ScHARR, which houses the Sheffield Unit of the Trent Institute for Health Services 
Research, facilitates a Working Group on Acute Purchasing. A list of interventions for 
consideration is recommended by the purchasing authorities in Trent and approved by the 
Purchasing Authorities Chief Executives (PACE) and the Trent Development and Evaluation 
Committee (DEC). A public health consultant from a purchasing authority leads on each 
topic and is assisted, as necessary, by a support team from ScHARR which provides help 
including literature searching, health economics and modelling. A seminar is then led by the 
consultant on the particular intervention where purchasers and provider clinicians consider 
research evidence and agree provisional recommendations on purchasing policy. The 
guidance emanating from the seminars is reflected in this series of Guidance Notes. 
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EXECUTIVE SUMMARY 
 
Stroke is a major cause of mortality and morbidity. It has been estimated that over 4% of 
NHS resources are devoted to the management of stroke, with long-term rehabilitation 
DFFRXQWLQJ IRU D VLJQLILFDQW SURSRUWLRQ RI WKH WRWDO DPRXQW µ7KH +HDOWK RI WKH 1DWLRQ¶
document set a target of 40% reduction in the death rate for coronary heart disease and 
stroke in people under 65 and for stroke in people aged 65-74 by the year 2000. 
 
There is significant scope for the secondary prevention of stroke through the long-term use 
of aspirin and oral anticoagulants. However, these treatments may lead to further problems 
if the initial stroke was haemorrhagic in nature. Computed Tomography (CT) scans of the 
head can be used to identify haemorrhagic strokes.  
 
This paper uses published data on the benefits of secondary prevention in the management 
of ischaemic stroke, combined with data on the costs of CT scans in the Trent Region and 
drug costs from the Drug Tariff, to identify the additional costs and benefits of using CT 
scanning in the management of stroke compared to using a diagnostic clinical scoring 
system or assuming that all strokes are ischaemic. 
 
The cost per life saved by scanning rather than using the clinical diagnosis scoring system 
ranges from £6,878 to £9,221, depending on the estimated effect of administering 
antiplatelet therapy to patients following a haemorrhagic stroke. Even at the upper end of 
this range, CT scanning in the management of stroke produces benefits at a cost which 
compares well with many procedures currently available within the NHS. 
 
A purchasing strategy supporting the routine CT scanning of stroke patients likely to benefit 
from secondary prevention should be adopted. There should be a distinction between those 
patients requiring an urgent scan, and those requiring a scan as soon as reasonably 
possible within two weeks of the onset of symptoms i.e. before it becomes impossible to 
distinguish haemorrhagic from ischaemic strokes using a CT scan. 
 
Such a policy is not only supported by the evidence of clinical and cost-effectiveness 
presented in this report, but is also consistent with the only existing professional guidelines 
for the management of acute stroke, published by the Royal College of Physicians and the 
.LQJ¶V)XQG)RUXP 
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1. INTRODUCTION 
 
1.1 Computed Tomography in the Management of Transient Ischaemic 
 Attack and Stroke 
 
Stroke is a major cause of mortality and morbidity. In 1991 it was the cause of 12% of all 
deaths in England, and about half of all those who survive a stroke will be left significantly 
disabled.1 Due to the resultant disability and need for prolonged rehabilitation, stroke 
accounts for 4.4% of total National Health Service (NHS) expenditure.1 
  
µ+HDOWKRIWKH1DWLRQ¶2 targets call for : 
x a reduction in the death rate for coronary heart disease and stroke in people under 65 by 
at least 40% by the year 2000 (baseline 1990); and 
x a reduction in the death rate for stroke in people aged 65-74 by at least 40% by the year 
2000 (baseline 1990).1  
 
A transient ischaemic attack (TIA) is a marker of vascular disease and indicates that the 
patient is at risk of stroke and other serious vascular events. 
 
A stroke may be ischaemic (85%) or haemorrhagic (15%). Haemorrhagic strokes can be 
further classified into either primary intracerebral haemorrhages - bleeding into the brain, or 
subarachnoid haemorrhages (SAH) - bleeding around the brain. Antiplatelet therapy and 
oral anticoagulants have proven benefit in terms of the management of TIA and long-term 
secondary prevention following an ischaemic stroke. There is no evidence of the effect of 
giving these treatments to patients with haemorrhagic strokes, but both are associated with 
haemorrhagic complications. Therefore, it is assumed that such treatment would have an 
adverse effect on outcome. 
 
Computed Tomography (CT) scans of the head can be used to confirm the diagnosis of 
stroke, and to differentiate between ischaemic, haemorrhagic and non-stroke lesions. 
However, the overall clinical and cost-effectiveness of CT scanning in the management of 
TIA and stroke remains uncertain. 
 
An agreement on the role of CT scanning is central to the development of shared care 
guidelines for the management of TIA and stroke. 
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1.2. Stroke and Transient Ischaemic Attack : Incidence and Prognosis 
 
Table 1: Incidence of Stroke and Transient Ischaemic Attack 
  per 100,000 Population per Year3 
 
EVENT INCIDENCE 
STROKE: 
 
Cerebral infarction 202 
Primary intracerebral haemorrhage 26 
Subarachnoid haemorrhage 12 
Total 240 
 
 
TIA:  
Carotid territory 34 
Other 8 
Total 42 
 
The overall 30 day case fatality rate following a first-ever stroke is 19%, but there is 
considerable variation by pathological type: 3,4,5,6,7,8,9,10 
 
Cerebral infarction    10% 
Primary intracerebral haemorrhage  50% 
Subarachnoid haemorrhage   46% 
 
The overall one year mortality rate is 31%, varying by pathological type as follows: 
 
Cerebral infarction    23% 
Primary intracerebral haemorrhage  62% 
Subarachnoid haemorrhage   48% 
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The proportion of all survivors assessed as being functionally independent at one year 
varies by pathological type as follows: 
 
Cerebral infarction    65% 
Primary intracerebral haemorrhage  68% 
Subarachnoid haemorrhage   76% 
 
The risk of stroke following a TIA is highest in the first year, at about 11%, falling to a 
constant rate of 5.5% per year thereafter. The risk of death is about 7% per year (one and a 
half times normal), mostly from stroke or myocardial infarction. 
 
There is good evidence from OPCS data that the mortality rate from stroke has consistently 
fallen in this country over the past 20 years, although the rate of decline may now have 
slowed. The cause(s) of this decrease is much debated, however, with the expected 
increase in both the number and proportion of elderly people in the population, the overall 
incidence of stroke and TIA is likely to increase in the coming years. 
 
1.3. The Management of Transient Ischaemic Attack and Stroke :  
 Effective Therapeutic Interventions 
 
1.3.1. Transient Ischaemic Attack 
 
The appropriate management of hypertension (and possibly hypercholesterolaemia) is likely 
to reduce the risk of a future stroke, as will the cessation of smoking, but the effect of such 
strategies has not been quantified.11 
 
Meta-analysis has indicated that antiplatelet drugs reduce the risk of future serious vascular 
events (stroke, myocardial infarction or vascular death) by about one quarter.12 This equates 
to a three year benefit of about 40 vascular events avoided per 1,000 patients treated. 
Treatment should commence immediately and is probably required indefinitely. 
 
Oral anticoagulation is indicated when a definite source of cardiac embolism has been 
identified, and for patients with atrial fibrillation. It is estimated that 90 serious vascular 
events will be prevented if 1,000 such patients are anticoagulated for one year.13 Antiplatelet 
therapy has a less significant protective effect in this group of patients (40 events prevented 
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per 1,000 patients treated for one year), but can be used in those patients for whom an 
anticoagulant is contraindicated. 
 
Finally, for those patients in whom further investigation reveals carotid stenosis of greater 
than 70%, carotid endarterectomy is generally more effective than medical treatment alone. 
Following surgery, there is a 5% reduction in the three year risk of any disabling or fatal 
stroke (or surgical death).14 
 
1.3.2.  Stroke 
 
(i) Haemorrhagic stroke 
In patients with a SAH, oral nimodipine (a calcium antagonist) reduces the incidence of 
cerebral ischaemia and poor outcome by about one third.15 These patients need to be 
identified promptly so that neurosurgical intervention can be considered. Similarly, 
neurosurgical intervention may be required following a cerebellar stroke because of the risk 
of obstructive hydrocephalus. 
 
(ii)  Ischaemic stroke - acute phase 
The International Stroke Trial Collaborative Group has recently published the results of a 
major, randomised trial of up to 14 days of antithrombotic therapy (aspirin and/or heparin) 
started as soon as possible after an acute ischaemic stroke.16 At this stage the routine use 
of low or medium-dose subcutaneous heparin cannot be recommended, although further 
research may identify certain groups of patients who could benefit from such treatment. 
However, the early use of aspirin 300mg daily was associated with a reduction in the 
number of deaths or recurrent strokes (10 per 1,000 patients treated) in the first few weeks 
after the acute event. Although this benefit was not as great as anticipated, and was not 
maintained at six months, similar results have been reported by the Chinese Acute Stroke 
Trial17. The immediate use of aspirin should be considered, therefore, in all patients with 
acute ischaemic stroke, once the diagnosis has been confirmed. 
 
A recent US study showed an improved clinical outcome at three months for patients with 
acute ischaemic stroke treated within three hours with the thrombolytic, tissue plasminogen 
activator (t-PA).18 However, there was no significant reduction in mortality, and there was an 
increased incidence of symptomatic intracerebral haemorrhage in those treated with t-PA. 
The practical difficulties involved in treating such patients within three hours of the onset of 
stroke, and the equivocal results of previous studies of thrombolytic therapy (including trials 
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stopped because of unacceptable rates of intracerebral haemorrhage) dictate that the 
routine use of such treatment cannot be recommended at this stage. Again, future studies 
may identify discrete sub-groups of patients with ischaemic stroke who may benefit. 
 
(iii)  Ischaemic stroke - longer term 
Antihypertensive treatment is likely to reduce the absolute risk of subsequent vascular 
events, but should be deferred for at least a few days after the onset of stroke.19 
 
Long-term antiplatelet therapy should be offered to patients following an ischaemic stroke, 
as this has been shown to reduce the risk of future serious vascular events by about a 
quarter (a three year benefit of about 40 vascular events avoided per 1,000 patients 
treated).12 As stated above, such treatment should be started as soon as possible after the 
onset of symptoms. 
 
Anticoagulant therapy is indicated for those patients with minor ischaemic strokes who are in 
atrial fibrillation.13 At present there is no evidence to support starting such treatment within 
two weeks of the onset of symptoms. Antiplatelet therapy is an alternative in those patients 
for whom an anticoagulant is contraindicated. 
 
Finally, patients who make a good functional recovery following an ischaemic stroke in the 
territory of the internal carotid artery should be investigated with a view to a carotid 
endarterectomy being performed.14 
 
1.4. Dangers of Inappropriate Treatment 
 
There is little evidence on the dangers of inappropriate treatment, specifically, the treatment 
of haemorrhagic stroke with antiplatelet therapy (e.g. aspirin) or anticoagulant (e.g. 
warfarin). 
 
Warfarin is certainly a known aetiological factor in the incidence of intracerebral 
haemorrhage in the general population. In a review of the evidence, Kase reported that 
warfarin was associated with bleeding complications in about 7-8% of patients.20 Although 
intracerebral haemorrhage accounts for only 0.5-1.5% of all these bleeding events, the 
prognosis is very poor, and the risk increases with age. Overall, warfarin has been 
estimated to increase between 8-fold and 11-fold the risk of intracerebral haemorrhage, as 
compared with non-anticoagulated individuals with similar risk factor profiles. Therefore, 
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even in the absence of evidence of a deleterious effect (and it is difficult to envisage such 
evidence being collected), it is reasonable to assume that warfarin is contraindicated in 
patients with a haemorrhagic stroke. 
 
Similarly, there is no evidence on the outcome in patients with a haemorrhagic stroke 
treated with antiplatelet therapy. However, there is circumstantial evidence from the work of 
WKH$QWLSODWHOHW7ULDOLVWV¶&ROODERUDWLRQ12 In these studies, compared to controls, there was 
an increased incidence of haemorrhagic stroke in patients at risk of occlusive vascular 
disease who were treated with antiplatelet therapy. This increase was non-significant in 
WKRVHFODVVLILHGDVµKLJKULVN¶SDWLHQWVEXWVLJQLILFDQWLQWKRVHSDWLHQWVFODVVLILHGDVµORZULVN¶
in whom the antiplatelet therapy was being used for the primary prevention of serious 
YDVFXODUHYHQWV,QWKHVHµORZULVN¶SDWLHQWVWKLVLQFUHDVHGLQFLGHQFHRIKDHPRUUKDJLFVWURNH
largely accounted for the lack of a significant overall reduction in vascular mortality. Thus, it 
would appear that antiplatelet therapy is also contraindicated in patients with a 
haemorrhagic stroke, although the effect on outcome in these patients cannot be quantified.
 8 
2. USE OF COMPUTED TOMOGRAPHY IN THE MANAGEMENT OF 
 TRANSIENT ISCHAEMIC ATTACK AND STROKE : SUMMARY OF 
 EVIDENCE OF EFFECTIVENESS 
 
2.1 Why Computed Tomography and not Magnetic Resonance Imaging? 
 
&RPSXWHG 7RPRJUDSK\ LV JHQHUDOO\ DVVXPHG WR EH WKH µJROG-VWDQGDUG¶ GLDJQRVWLF WHVW IRU
stroke, but there are certain reservations which accompany this assumption. CT is quick and 
largely non-invasive, and is extremely accurate in distinguishing haemorrhage from 
infarction even moments after the event (although the best time to detect small 
haemorrhages is probably at 24-48 hours). However, the density of haemorrhages declines 
with time, so that by 14-21 days the haematoma can be isodense with brain and thus 
invisible.21 Also, 40-50% of diagnosed infarcts are not visualised until 48 hours after the 
event and, thus, a negative scan during this period cannot exclude a cerebral infarct.22 
Finally, the cerebellum and brain stem are not well evaluated by CT because the bony 
casing of the posterior fossa tends to obscure these structures. 
 
Magnetic resonance imaging (MRI) certainly has the advantage over CT with respect to the 
identification of structures in the posterior fossa, but has a longer imaging time, which can 
introduce movement artifacts (a potential problem with restless stroke patients). 
 
One recent study attempted to compare the performance of the two techniques in the early 
detection of ischaemic stroke or haemorrhage.23 This was a prospective study of acute 
strokes, with patients receiving a baseline clinical assessment followed by baseline imaging 
studies (concurrent CT and MRI scans). The process was repeated at intervals of 24 hours, 
three to five days and three months. The study neurologists who performed the clinical 
assessment were blinded to the results of imaging, as were the study radiologists to the 
clinical findings. A total of 80 patients were recruited (the refusal rate was not reported) 
within 24 hours of the onset of symptoms; 68 of these being recruited within four hours. 
Seventy five of the patients recruited were cerebral infarcts and only five were due to 
haemorrhage; those patients with the clinical diagnosis of SAH were excluded from the 
study. Neither technique was significantly superior in the very early detection of either 
haemorrhage or infarction although, in the case of haemorrhage, this is not surprising given 
the small number. Significantly more baseline CT scans were reported as normal in those 
patients whose symptoms had resolved within 24 hours and whose scans, therefore, should 
not have shown evidence of an acute event. 
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Therefore, given also that CT is cheaper and much more readily available than MRI, it 
SUREDEO\GHVHUYHVWREHUHJDUGHGDVWKHµJROGVWDQGDUG¶ 
 
2.2. How Can the Effectiveness of Computed Tomography be Assessed? 
 
CT scanning of the head is the most widely used imaging technique in the evaluation of 
stroke.24 However, there have been no randomised controlled trials or observational studies 
to compare the outcome of stroke, or TIA, patients receiving a CT scan with those not 
receiving a scan. A measure of effectiveness which can be assessed from the literature, 
KRZHYHULVWKHµ\LHOG¶RID&7VFDQSHUIRUPHGRQWKHVHSDWLHQWVGHILQHGDVWKHSURSRUWLRQ
of the tests performed that detect a pathologically relevant or potentially treatable condition 
that influences management.25 
 
2.3. Computed Tomography and Transient Ischaemic Attack 
 
In the Oxfordshire Community Stroke Project, 512 patients with transient neurological 
symptoms either were referred by their GPs or presented at a hospital.7 Following 
assessment by the study team, only 195 (38%) were classified with the clinical diagnosis of 
TIA, a further 46 (9%) were classified as possible TIAs, and the remainder were diagnosed 
as suffering from a wide variety of conditions including two meningiomas. Of the 195 TIAs, 
184 were classified as incident TIAs, the remaining patients having had a previous TIA or 
stroke. Of the 184 incident TIAs, 120 (65%) received a CT scan.26 The results were as 
follows: 
 
x No intracranial (subarachnoid or primary intracerebral) haemorrhage reported; 
x No structural lesion (tumour, aneurysm or arteriovenous malformation) reported; 
x Ischaemic lesions reported in 32 scans (27%). 
 
However, when the positive reports were compared with the clinical features, the ischaemic 
OHVLRQZDVIRXQGWREHVLWXDWHGLQDQDUHDRIWKHEUDLQDSSURSULDWHWRWKHSDWLHQWV¶V\PSWRPV
in only 14 cases (12%). Also, there were no significant differences in the clinical features, 
the duration of the attacks or the prognosis of patients with and without ischaemic lesions on 
CT. However, the numbers were small and, therefore, this information, was of no additional 
value to the clinician. 
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Similar results were reported in a Finnish hospital-based study of acute cerebrovascular 
events,27 although it might be assumed that patients with an atypical course to their disease 
might be over-represented in such a study. The CT results for the 51 patients with a 
presumed TIA were as follows: 
 
x No intracranial haemorrhage reported; 
x No structural lesion reported; 
x Ischaemic lesions reported in 3 scans (6%); 
x Non-specific lesions reported in 15 scans (29%) - largely local or generalised atrophy of 
varying severity. 
 
None of the non-specific changes was felt to be of clinical relevance, and the relevance of 
the ischaemic lesions was not discussed. 
 
Similarly, a prospective study of 469 consecutive patients considered for carotid 
endarterectomy was performed in the US over a five year period.28 Of these, 237 (51%) 
were diagnosed as having suffered TIA, and all patients went on to receive a duplex scan of 
the carotid vasculature in the neck, a CT scan and a carotid arteriography. No intracranial 
haemorrhages or structural lesions were reported in any of the 469 scans. Ischaemic lesions 
were reported in 119 of the 469 scans (25%) but, unfortunately, this information was not 
provided separately for patients with TIA. However, the result of the CT scan did not 
influence the decision to proceed with surgery in any of the cases, and neither did the 
findings correlate with postoperative morbidity or mortality. It is impossible to know exactly 
how much emphasis the study team did place on the result of the CT scan, but the 
proportion of abnormal scans was certainly very similar in both the operative (23%) and non-
operative (27%) groups. 
 
The results from these studies suggest that there is no clinical benefit to be gained from 
routinely CT scanning patients with TIA as clinically diagnosed by a specialist. Significantly, 
intracranial haemorrhage was not reported in any of these studies in patients fulfilling the 
main criterion for diagnosing a TIA, namely that the symptoms resolved within 24 hours. 
This suggests that it is useful to maintain the distinction between TIA and minor ischaemic 
stroke, even if their management and prognosis are very similar, as the risk of a supposed 
ischaemic event actually being haemorrhagic appears to increase with symptoms of longer 
duration. 
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2.4 Computed Tomography and Stroke 
 
In assessing the yield from the CT scanning of stroke patients, one option is to compare the 
results of such scans with the clinical diagnosis of those same patients. The evidence exists 
to enable this comparison to be made for the two issues central to the management of 
stroke: distinguishing stroke from non-stroke, and distinguishing haemorrhagic from 
ischaemic stroke. 
 
2.4.1 Distinguishing Stroke from Non-stroke 
 
After the first two years of the Oxfordshire Community Stroke Project, the referrals to the 
study team were evaluated.29 For the 736 referrals of acute neurological deficit, the clinical 
diagnosis of the study team was as follows: 
 
Clinically definite first stroke   325 
TIA        74 
Previous stroke    176 
Referred in error      29 
Clinically not stroke    132 
 
2I WKH  µFOLQLFDOO\ GHILQLWH ILUVW VWURNHV¶ ILYH QRQ-stroke lesions (two subdural 
haematomas, two gliomas and one metastasis) were detected on CT scan (90% of patients 
receivinJDVFDQ2IWKHµFOLQLFDOO\QRWVWURNHV¶WKHPDMRULW\RIZKRPGLGQRWUHFHLYHD
CT scan, three were reclassified as a first stroke following CT. 
 
This gives a false positive rate of 1.5% and a false negative rate of 1% for the study 
neurologists in the clinical diagnosis of stroke, although these figures may have been higher 
if all patients had been scanned. 
 
Similarly, in an Italian community-based study of stroke, of 379 patients diagnosed as 
µFOLQLFDOO\GHILQLWHILUVWVWURNHV¶E\WKHVWXG\WHDPIour (1%) were found to have a subdural 
haematoma or tumour on CT scan (false positives).9 However, no figures were provided on 
the false negatives (those assessed as a non-stroke and subsequently diagnosed as a 
stroke following a CT scan). 
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In the Finnish hospital-based study (and therefore a selected population), the study 
neurologist had a false positive rate of 3.2% and false negative rate of 4.7% in diagnosing 
stroke compared to CT scan.27 
 
These three studies all incorporated specialist assessment of suspected strokes, and it can 
reasonably be assumed that non-specialist assessment would result in higher false positive 
and false negative rates. Indeed, the incidence of non-stroke lesions detected by CT 
scanning in patients with suspected stroke has been reported to be as high as 16%.21 The 
detection of non-stroke lesions on scans of suspected strokes is certainly an added bonus 
as, even though structural lesions such as subdural haematomas and tumours are likely to 
present again, if not detected by the scan, the prognosis will worsen with time. 
 
2.4.2 Distinguishing Haemorrhagic from Ischaemic Stroke  
 
Clinical scoring systems have been advocated for differentiating between haemorrhagic and 
ischaemic strokes when a CT scanner is unavailable. Two such systems have been 
HYDOXDWHG LQ WKH OLWHUDWXUH WKH *X\¶V +RVSLWDO VFRUH30 (alternatively known as the Allen 
score) and the Siriraj stroke score.31 Both these scores were developed to produce relative 
probabilities of haemorrhage and ischaemia for individual patients, and cut-off points can be 
XVHG WR FODVVLI\ VWURNHV DV µSUREDEO\ KDHPRUUKDJLF¶ µSUREDEO\ LVFKDHPLF¶ RU RI µXQFHUWDLQ
SDWKRORJ\¶ )RU WKH SXUSRVHV RI WKLV ZRUN WKHVH VFRULQJ V\VWHPV FDQ EH UHJDUGHG DV
standardised substitutes for thorough clinical assessment of acute stroke. 
 
The Guy's Hospital score is of most interest as this system was developed for use in the UK, 
and Table 2 summarises the expected results of using this score in the clinical assessment 
of 1,000 acute strokes. The figures are based on a study by Celani et al, in which 15% of 
the strokes were subsequently confirmed as haemorrhagic following a CT scan (consistent 
with the community based studies of the epidemiology of stroke).32 
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TABLE 2: Outcome of the Use of the Guy's Hospital Score in the   
  Clinical Assessment of 1,000 Acute Strokes 
 
OUTCOME GUY'S HOSPITAL SCORE 
     Number       (95%CI) 
Correctly Diagnosed 
Ischaemic Stroke 
                           
680 
 
(620-740) 
Wrongly Diagnosed 
Ischaemic Stroke  
(i.e. CT Shows 
Haemorrhage) 
 
 
 
70 
                              
 
 
(37-103) 
Correctly Diagnosed 
Haemorrhagic Stroke 
                             
43 
 
(17-69) 
Wrongly Diagnosed 
Haemorrhagic Stroke  
(i.e. CT Shows Ischaemia) 
 
 
17 
                              
 
(0-34) 
 
Uncertain Pathology 
                           
190 
 
(139-241) 
 
An estimate of the overall yield from the use of CT scanning in the assessment of the same 
1,000 acute strokes can thus be made: 
 
Yield = 1,000 - (680 + 43) = 277 = 27.7%. 
 
Thus, in 27.7% of cases a CT scan of the head would change the clinical diagnosis (or 
enable the diagnosis to be made) and alter the subsequent management of the patient. 
 
The false positive rate in the clinical diagnosis of stroke has been estimated at 4%.27,29 
Thus, for every 1,000 suspected strokes, CT scanning would reveal 40 non-strokes. The 
effect of these non-strokes on the estimate of the yield cannot be calculated, but it is likely 
to increase it. 
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3. COST AND BENEFIT IMPLICATIONS OF ADOPTING INTERVENTION 
 
As the studies identified in the literature review suggest that there is no clinical benefit to be 
gained from routinely scanning patients with TIA, there is no reason to conduct an economic 
evaluation of such a programme. However, there is good evidence that routinely scanning 
stroke patients will influence the subsequent management of a significant proportion of 
them, and evidence also exists on the effectiveness of the therapeutic interventions used in 
the management of ischaemic stroke.12,13 These two sources of information can form the 
basis of an economic evaluation, together with the following data on costs: 
 
Anticoagulant (warfarin 6mg daily, plus 8 INR tests at £1.64 each)  £34.11 per annum 
Antiplatelet (aspirin 300mg daily)      £1.61 per annum 
Non contrast CT scan of the head      £103.77 
Transport for an outpatient CT scan (minimum charge  
for a health transport vehicle with two crew)     £30.00 
 
Mean dose of warfarin and frequency and cost of INR tests taken from a review of the use 
of anticoagulants in primary care (personal communication, Framework for Appropriate Care 
Throughout Sheffield). 
The drug costs are taken from the Drug Tariff.33 
The CT scan and transport costs are the mean Extra-Contractual Referral (ECR) costs of 
these procedures within Trent.34 
 
3.1 Assumptions Made in the Economic Evaluation 
 
x In the absence of comparable data, the baseline outcome event rates for haemorrhagic 
strokes are assumed to be the same as for ischaemic strokes.12,13 
 
x Aspirin has been shown to increase the risk of fatal haemorrhagic stroke by 0.25% over 
three years in patients with a previous ischaemic stroke.12 The effect when given to 
patients with a previous haemorrhagic stroke can only be estimated, but the following 
options are considered: 
 A. Same risk as when given to patient with ischaemic stroke - 0.25% 
 B. Ten times the risk of giving it to patient with ischaemic stroke - 2.5% 
 C. Twenty five times the risk of giving it to patient with ischaemic stroke - 6.25% 
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x It is also assumed that patients with a haemorrhagic stroke who receive aspirin do not 
experience the mortality/morbidity benefits observed in patients with an ischaemic stroke. 
 
3.2 Estimates of the Cost per Life Saved for Various Scenarios 
 
Baseline. 1,000 acute strokes - none scanned or treated with aspirin or warfarin. 
 
1,000 acute strokes: - 850 ischaemic - 153 in atrial fibrillation (AF).35 
   - 150 haemorrhagic - 16 in AF.35 
Expected number of deaths in the 3 years following the acute stroke = 164. 
 
Scenario 1. 1,000 acute strokes - none scanned, but all treated with aspirin. 
 
Costs incurred - the cost of the aspirin. 
 
Table 3: Cost per Life Saved for Scenario 1 
 
OUTCOME OPTION A OPTION B OPTION C 
Number of Deaths 149 152 158 
Lives Saved with 
Respect to Baseline 
 
15 
 
12 
 
6 
Cost of Programme 
(£) 
4,582 4,578 4,565 
Undiscounted Cost 
Per Life Saved (£) 
305 382 761 
Discounted Cost 
Per Life Saved (£)* 
308 382 772 
*Costs and benefits (lives saved) discounted at a rate of 6% per annum (the rate currently recommended by the  
Treasury for use throughout the public sector). 
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Scenario 2. 1,000 acute strokes - all assessed using the Guy's Hospital score, and those 
classified as ischaemic treated with aspirin. 
 
Costs incurred - the cost of the aspirin. 
 
Table 4: Cost per Life Saved for Scenario 2 
 
OUTCOME OPTION A OPTION B OPTION C 
Number of Deaths 151 153 156 
Lives Saved with 
Respect to Baseline 
13 11 8 
Cost of Programme (£) 3,435 3,432 3,427 
Undiscounted Cost Per 
Life Saved (£) 
264 312 428 
Discounted Cost Per 
Life Saved (£) 
269 315 432 
 
Scenario 3. 1,000 acute strokes - all scanned and treated with aspirin or warfarin as 
appropriate. 
 
Costs incurred - the cost of the scans, aspirin and warfarin, and the transport costs for the 
240 patients not admitted to hospital (Hospital Episode Statistics suggest that 76% of acute 
strokes are currently admitted to hospital in Trent). 
 
Expected number of deaths in the 3 years following the acute stroke = 137. 
Lives saved with respect to baseline = 27. 
Cost of programme = £128,669. 
Undiscounted cost per life saved = £4,766. 
Discounted cost per life saved = £4,990. 
 
In order to estimate the cost per life year saved in each scenario, a number of assumptions 
would have to be made with respect to the age at which the acute stroke occurred (not 
available from the Antiplatelet Trialists' Collaboration),12 the persistence of benefits beyond 
the three year follow-up period and the life expectancy of this group of patients. Given the 
assumptions already made in the analysis, this was felt to be of limited value. 
 
3.3 Estimates of the Cost per Serious Vascular Event Avoided for Each 
 Scenario 
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Baseline. 1,000 acute strokes - none scanned or treated with aspirin or warfarin. 
 
Expected number of outcome events in the 3 years following the acute stroke: 
Non-fatal myocardial infarctions = 28. 
Non-fatal strokes = 138. 
Vascular deaths = 130. 
Total number of serious vascular events = 296. 
 
Scenario 1. 1,000 acute strokes - none scanned, but all treated with aspirin. 
 
Table 5: Cost per Serious Vascular Event Avoided for Scenario 1 
 
OUTCOME OPTION A OPTION B OPTION C 
Number of Non-Fatal 
Myocardial Infarctions 
20 20 20 
Number of Non-Fatal 
Strokes 
119 119 119 
Number of Vascular 
Deaths 
115 118 124 
    
Total Number of 
Serious Vascular 
Events 
254 257 263 
    
Serious Vascular 
Events Avoided with 
Respect to Baseline 
42 39 33 
Cost of Programme (£) 4,582 4,578 4,565 
Undiscounted Cost Per 
Serious Vascular Event 
Avoided (£) 
109 117 138 
Discounted Cost Per 
Serious Vascular Event 
Avoided (£) 
109 117 138 
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Scenario 2. 1,000 acute strokes - all assessed using the Guy's Hospital score, and those 
classified as ischaemic treated with aspirin. 
 
Table 6: Cost per Serious Vascular Event Avoided for Scenario 2 
 
OUTCOME OPTION A OPTION B OPTION C 
Number of Non-Fatal  
Myocardial Infarctions  
22 22 22 
Number of Non-Fatal 
Strokes 
123 123 123 
Number of Vascular 
Deaths 
118 120 123 
    
Total Number of 
Serious Vascular 
Events 
263 265 268 
    
Serious Vascular 
Events Avoided with 
Respect to Baseline 
33 31 28 
Cost of Programme (£) 3,435 3,432 3,427 
Undiscounted Cost Per 
Serious Vascular Event 
Avoided (£) 
104 111 122 
Discounted Cost Per 
Serious Vascular Event 
Avoided (£) 
104 111 123 
 
Scenario 3. 1,000 acute strokes - all patients scanned and treated with aspirin or warfarin 
as appropriate. 
 
Expected number of outcome events in the 3 years following the acute stroke: 
Non-fatal myocardial infarctions = 19. 
Non-fatal strokes = 92. 
Vascular deaths = 102. 
Total number of serious vascular events = 213. 
Serious vascular events avoided with respect to baseline = 83. 
Cost of programme = £128,669. 
Undiscounted cost per serious vascular event avoided = £1,550. 
Discounted cost per serious vascular event avoided = £1,621. 
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3.4. Summary of the Cost-effectiveness of Each Scenario 
 
Table 7: Summary of the Cost-effectiveness of Each Scenario 
 
SCENARIO LIVES 
SAVED 
UNDISCOUNTED 
(DISCOUNTED*) 
COST PER LIFE 
SAVED (£) 
SERIOUS 
VASCULAR 
EVENTS 
AVOIDED 
UNDISCOUNTED 
(DISCOUNTED*) 
COST PER 
SERIOUS 
VASCULAR 
EVENT AVOIDED 
(£) 
One 
1,000 Acute 
Strokes - None 
Scanned but All 
Treated with 
Aspirin: 
Option A 
Option B 
Option C 
 
 
 
 
 
 
15 
12 
6 
 
 
 
 
 
 
305 (308) 
382 (382) 
761 (772) 
 
 
 
 
 
 
42 
39 
33 
 
 
 
 
 
 
109 (109) 
117 (117) 
138 (138) 
Two 
1,000 Acute 
Strokes - All 
Assessed Using 
GHS,+ and Those 
Classified as 
Ischaemic 
Treated with 
Aspirin: 
Option A 
Option B 
Option C 
 
 
 
 
 
 
 
 
 
13 
11 
8 
 
 
 
 
 
 
 
 
 
264 (269) 
312 (315) 
428 (432) 
 
 
 
 
 
 
 
 
 
33 
31 
28 
 
 
 
 
 
 
 
 
 
104 (104) 
111 (111) 
122 (123) 
Three 
1,000 Acute 
Strokes - All 
Scanned And 
Treated with 
Aspirin or 
Warfarin as 
Appropriate 
 
 
 
27 
 
 
 
4,766 (4,990) 
 
 
 
83 
 
 
 
1,550 (1,621) 
* Costs and benefits discounted at a rate of 6% per annum. 
*+6*X\¶V+RVSLWDOVFRUH
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3.5. Sensitivity Analysis 
 
The two variables that impact most on these analyses are: 
 
1. The effect of aspirin when given to patients with a previous haemorrhagic stroke - a range 
of estimates has been provided based on differing assumptions as to the magnitude of this 
effect. 
 
2. The cost of a non-contrast CT scan of the head - the mean ECR cost of this procedure 
was used in the analyses, but the actual cost ranged between £44.69 and £200 for the 
various providers within the Trent Region.34 
 
Using this information, a range of estimates can be provided for Scenario 3: 
 
Discounted cost per life saved = £2,682 to £8,220. 
 
Discounted cost per serious vascular event avoided = £871 to £2,670. 
 
3.6 Crude Estimate of the Net Cost of Each Scenario 
 
The analysis presented earlier in this section uses gross costs. However, there is also 
potential for cost savings from vascular events avoided. Secondary care cost savings have, 
therefore, been calculated for each scenario, based on the number of serious vascular 
events avoided. These savings are purely notional, as no true savings can be made until a 
hospital ward closes or staffing levels are reduced, but the analyses do demonstrate the 
monetary value of some of the benefits arising from each scenario. 
 
The following secondary care costs are again the mean ECR costs attributed to these 
diagnoses within the Trent Region.34 
 
Acute myocardial infarction (uncomplicated) - £1,510 
Stroke - £2,216 
Vascular death - each death attributed to either an acute myocardial infarction or stroke (in 
the appropriate proportion for each scenario) and assumed to consume the same 
resources. 
Table 8: Estimate of the Net Cost of Each Scenario 
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SCENARIO COST OF 
PROGRAMME 
(£) 
SERIOUS 
VASCULAR 
EVENTS 
AVOIDED: 
MI/STROKE/VD+ 
COST 
SAVINGS 
(£) 
UNDISCOUNTED 
NET COST/ 
SAVING OF 
PROGRAMME 
(£) 
DISCOUNTED 
NET COST/ 
SAVING OF 
PROGRAMME* 
(£) 
One 
1,000 Acute 
Strokes - 
None 
Scanned, but 
All Treated 
with Aspirin: 
Option A 
Option B 
Option C 
 
 
 
 
 
 
 
4,582 
4,578 
4,565 
 
 
 
 
 
 
 
8/19/15 
8/19/12 
8/19/6 
 
 
 
 
 
 
 
84,286 
78,266 
66,224 
 
 
 
 
 
 
 
79,704 
73,688 
61,659 
 
 
 
 
 
 
 
75,736 
70,120 
58,694 
Two 
1,000 Acute 
Strokes - All 
Assessed 
Using GHS, # 
and Those 
Classified as 
Ischaemic 
Treated with 
Aspirin: 
Option A 
Option B 
Option C 
 
 
 
 
 
 
 
 
 
 
3,435 
3,432 
3,427 
 
 
 
 
 
 
 
 
 
 
6/15/12 
6/15/10 
6/15/7 
 
 
 
 
 
 
 
 
 
 
66,471 
62,443 
56,400 
 
 
 
 
 
 
 
 
 
 
63,036 
59,011 
52,973 
 
 
 
 
 
 
 
 
 
 
59,596 
55,773 
49,936 
Three 
1,000 Acute 
Strokes - All 
Scanned and 
Treated with 
Aspirin or 
Warfarin as 
Appropriate 
 
 
 
128,669 
 
 
 
9/46/28 
 
 
 
174,340 
 
 
 
45,671 
 
 
 
37,786 
+ MI: Myocardial Infarction    VD: Vascular Death 
* Costs and benefits discounted at a rate of 6% per annum. 
#
 *+6*X\¶V+RVSLWDOVFRUH 
 
 
3.7 Marginal Analysis 
 
In the absence of a CT scan, clinical assessment of an acute stroke would be followed by 
the use of aspirin in those classified as ischaemic (Scenario 2). Therefore, a marginal 
analysis comparing Scenario 3 against Scenario 2 is required to provide purchasers with an 
estimate of the cost-HIIHFWLYHQHVVRI6FHQDULRFRPSDUHGWRWKHµQH[WEHVW¶DOWHUQDWLYH7KH
discounted costs and benefits of the two scenarios are as follows: 
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 Cost (£) Lives Saved with 
Respect to 
Baseline  
Serious Vascular 
Events Avoided 
with Respect to 
Baseline 
SCENARIO 3 127,734 25.6 78.8 
 
   
SCENARIO 2:    
OPTION A 3,251 12.1 31.2 
OPTION B 3,248 10.3 29.3 
OPTION C 3,243   7.5 26.4 
 
Thus, the discounted marginal costs and benefits of Scenario 3 compared to Scenario 2 are: 
 
 Cost (£) Lives Saved  Serious Vascular 
Events Avoided 
OPTION A 124,483 13.5 47.6 
OPTION B 124,486 15.3 49.5 
OPTION C 124,491 18.1 52.4 
 
This produces a discounted marginal cost per life saved of: 
 
OPTION A £9,221 
OPTION B £8,136 
OPTION C £6,878 
 
and a discounted marginal cost per serious vascular event avoided of: 
 
OPTION A £2,615 
OPTION B £2,515 
OPTION C £2,376 
 
3.8 Validity of the Economic Evaluation 
 
In the absence of a randomised controlled trial or observational study comparing the 
outcome of stroke patients receiving a CT scan against those not receiving a scan, data had 
to be drawn from a number of sources. These data were far from ideal even where they 
existed, the following factors detracting from the internal validity of the analyses: 
x The data on the effects of using antiplatelet therapy for the secondary prevention of 
ischaemic stroke were taken from the Antiplatelet Trialists' Collaboration.12 The analyses 
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were performed on patients with a previous history of stroke or TIA and most patients 
were entered into trials several weeks after the index event. The effects of treatment for 
ischaemic stroke may have been distorted by the inclusion of TIAs although, in the trials 
with individual patient information available, there was no significant difference in the 
outcome of the two patient groups. In addition, the beneficial effects of treatment, and the 
risks of inappropriate treatment, may well be greater the earlier treatment is initiated. 
 
x The analyses of the benefits of both antiplatelet and anticoagulant therapy covered 
periods of follow-up between two and three years, but it is likely that the beneficial effects 
persist beyond this point. 
  
x The non-strokes detected by scanning suspected strokes (mainly subdural haematomas 
and tumours) may be treatable, but the impact this would have on the cost-effectiveness 
of routine scanning cannot be predicted. Similarly, the potential benefit of referring SAHs 
and cerebellar strokes to the neurosurgeons for possible intervention has not been 
incorporated in the analysis. 
  
x The effects, both beneficial and detrimental, of giving antiplatelet therapy to patients with 
haemorrhagic strokes remain unknown and have only been estimated in the analyses. 
  
x The primary and secondary care costs (and the longer-term community care costs) are 
not incorporated in the analyses, and the cost of suffering endured by patients and their 
carers has not been considered either. 
 
In addition, there are a number of factors which will impact on the external validity or 
generalisability of the analyses: 
 
x It has been assumed that there is some spare capacity for obtaining CT scans, and that 
additional capital investment is not required. If this is not the case, and with the cost of 
CT scanners varying from about £300,000 to £1 million, the cost of implementing 
Scenario 3 would rise significantly. However, a survey performed in 1992/93 of all UK 
hospital consultant geriatricians, general physicians and neurologists (84% response 
rate) reported that 74% of consultants had on-site CT scanning facilities and that 90% 
could obtain a CT scan for patients with a stroke within two weeks of the onset of 
symptoms.36 The proportion of consultants with on-site CT scanning facilities will certainly 
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have increased over the past four years, although this will not necessarily have led to 
increased availability. 
 
x The marginal costs and benefits of Scenario 3 will vary between areas, as the proportion 
of acute stroke patients currently receiving a CT scan varies between areas. In the 
published literature the proportion of all acute stroke patients admitted to hospital has 
ranged from 54% to 76%10 and the proportion of those admitted who receive a CT scan 
has varied between 17% and 50%.37,38 In addition, the cost benefit ratio may be less 
favourable than that anticipated if the cases with most to gain are those currently 
receiving a CT scan. 
 
Finally, it is evident that discounting the costs and benefits at a rate of 6% per annum (as 
currently recommended by the Treasury) has little effect on either the absolute or relative 
cost-effectiveness of the various scenarios. This is not surprising, as discounting is only 
really of importance when the timing of costs and benefits varies greatly between scenarios 
and, in this instance, the period of interest is only three years. 
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4. OPTIONS FOR PURCHASERS AND PROVIDERS 
 
A summary of the cost-effectiveness of Scenarios 1, 2 and 3 is provided in Table 7. To help 
put these data in context, the cost per life saved of a range of other interventions is provided 
below.39 
 
Table 9: The Cost per Life Saved of Other Interventions 
 
INTERVENTION COST PER LIFE YEAR  1991 
Opportunistic lipid screening in General Practice  £3,671 
Nicotine gum compared to physician advice against 
cigarette smoking in primary care: men aged 35-39 
£3,934 
Coronary care unit provision for people experiencing MI £4,974 
Breast cancer screening for women aged 45 to 65 £8,417 
Formal screening for cervical cancer £9,070 
Intensive care treatment for patients with multiple trauma £9,977 
Use of neonatal intensive care unit: BW 500 to 999g £11,400 
Kidney transplant with immunosuppressive therapy £17,400 
Haemodialysis £27,000 
 
 
All three scenarios compare very favourably to the above interventions in terms of the cost 
per life saved. Although no comparable costs per vascular event avoided were found in the 
literature, all three scenarios show putative net savings when the secondary care costs 
attributed to these events are taken into account (Table 8). The relative cost-effectiveness of  
the three scenarios is difficult to assess because of the lack of data relating to the effect of 
administering antiplatelet therapy to a patient with a haemorrhagic stroke. 
 
Scenario 1 is certainly equitable, but not necessarily realistic. Clinicians are unlikely to be 
persuaded to treat all strokes empirically with antiplatelet therapy, in the knowledge that 
15% will be haemorrhagic. 
 
In Section 2.4 it was concluded that the clinical classification of stroke would be incorrect or 
indeterminate in 27.7% of cases. Even if Scenario 2 was modified to include CT scanning of 
those classified as indeterminate, the error rate would still be 8.7%. In addition, the potential 
benefits of an anticoagulant would be wasted, as extensive discussion with local clinicians 
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(GPs and hospital consultants) has not identified a single one who would prescribe 
anticoagulant therapy following a stroke without a CT scan. 
 
Scenario 3 results in considerably more lives saved and vascular events avoided than any of 
the alternatives. Significantly, the marginal cost per life saved of Scenario 3 compared to 
Scenario 2 ranges from £6,878 to £9,221, depending on the estimated effect of 
administering an antiplatelet to patients following a haemorrhagic stroke (Section 3.7). This 
marginal analysis offers an estimate of the cost-effectiveness of Scenario 3 compared with 
WKHµQH[WEHVW¶DOWHUQDWLYHDQGWKHUHVXOWVVWLOOFRPSDUHYHU\IDYRXUDEO\ZLWKWKRVHSUHVHQWHG
in Table 9. 
 
It is unrealistic to assume, however, that all strokes can, or should, be scanned. In the 
Oxfordshire Community Stroke Project, 6.5% of patients with an acute stroke had died 
before a scan could be arranged, 9.2% of patients were too ill and, in a further 2.4% of 
cases, either the patient or his/her relatives refused.3 It is important to try to identify those 
patients likely to die early or suffer severe long-term disability, as a CT scan will cause 
unnecessary distress for the patient and his/her family, and there is no evidence that the 
severely disabled will benefit from long-term secondary prevention. The trials of such 
therapy excluded patients who had suffered disabling strokes.12,13 Although disability 
fluctuates markedly over the first week, there is good evidence that the level of disability at 
one week is of prognostic importance, and other prognostic features predicting death or 
long-term disability (such as loss of consciousness, complete paralysis and urinary 
incontinence) are well established.10 
 
In addition, a CT scan will not influence the subsequent management of those patients in 
whom antiplatelet and anticoagulant therapy are contraindicated. 
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5. DISCUSSION AND CONCLUSIONS 
 
There is no evidence to support a policy of routinely scanning patients with a suspected TIA. 
However, many patients referred to a specialist as suspected TIAs will be suffering from 
other conditions. This supports the view that patients with transient neurological symptoms 
should be referred urgently to a neurovascular physician for assessment,11 because of both 
the diagnostic uncertainty and the need for suitable interventions to be introduced 
immediately to gain the greatest benefit. Such a policy will need to be agreed and developed 
at a local level. 
 
However, a purchasing strategy supporting the routine CT scanning of stroke patients likely 
to benefit from secondary prevention should be adopted. There should be a distinction, as 
indicated below, between those patients requiring an urgent scan, and those requiring a 
scan as soon as reasonably possible within two weeks of the onset of symptoms i.e. before 
it becomes impossible to distinguish haemorrhagic from ischaemic strokes. Priority should 
be given to scanning these patients, as the Stroke Trials have indicated at least short-term 
benefits following the early use of aspirin in patients with ischaemic strokes.16,17 There are 
no age restrictions for these recommendations. 
 
Table 10: Indications for a Computed Tomography Scan Following an Acute 
  Stroke 
 
URGENT SCAN INDICATED SCAN INDICATED AS SOON AS POSSIBLE 
(BUT WITHIN TWO WEEKS) 
x Patient with evolving, unstable signs 
x Patient already on antiplatelet, 
anticoagulant or thrombolytic therapy at 
the time of his/her stroke 
x Patient known to be suffering from a 
bleeding disorder 
x Patient with suspected cerebellar stroke 
x Patient with suspected SAH 
x Patient being considered for treatment 
with antiplatelet, anticoagulant or 
thrombolytic therapy 
x Patient with uncertain diagnosis of stroke 
x Patient being considered for carotid 
endarterectomy 
 
Patients for whom antiplatelet and anticoagulant therapy are contraindicated should not 
receive a CT scan, unless one of the above indications applies. Neither is it appropriate to 
scan (routinely) moribund patients. At this stage there is no evidence to support the routine 
scanning of those patients suffering a severely disabling stroke (as assessed at one week) 
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but, if sufficient resources are available, such patients should be scanned if drug treatment 
of an ischaemic stroke would be considered appropriate. 
 
Such a policy is not only supported by the evidence of clinical and cost-effectiveness 
presented in this report, but is also consistent with the only existing professional guidelines 
for the management of acute stroke, published by the Royal College of Physicians40 and the 
.LQJ¶V)XQG)RUXP24 
 
The implications of such a policy will need to be addressed at a local level. This will involve 
an assessment of the additional cost of a change in practice (current practice within each 
area will need to be assessed to identify the baseline position), and the provision of GP 
access to scanners will need to be negotiated. To avoid unnecessary hospital admissions, 
such access will need to be provided, either directly or via an urgent outpatient appointment. 
 
Finally, assuming recommendations to scan routinely those stroke patients likely to benefit 
from secondary prevention are adopted, the feasibility of establishing a stroke register, 
possibly across Trent, should be examined. The maintenance of such a register would be 
facilitated by a policy of scanning the majority of strokes, and it would be of immense value 
as an aid to future audit and research projects. 
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6. USE OF COMPUTED TOMOGRAPHY : SUMMARY MATRIX 
 
PATIENT GROUP AND 
PROPOSED 
INTERVENTION 
PATIENT CRITERIA 
(GUIDELINES NOT 
PROTOCOLS) 
ESTIMATED FUTURE 
ACTIVITY 
OPPORTUNITY FOR 
COST SAVING 
AUDIT/RESEARCH 
ACTIVITY 
EFFECTS THAT 
COULD BE 
EXPECTED IN 
RELATION TO 
STARTING POINT 
COST- 
EFFECTIVENESS 
All those presenting 
with a TIA. 
 
No benefit from routine CT 
scanning. 
N/A N/A N/A N/A N/A 
All those presenting 
with an acute stroke 
who meet the agreed 
criteria will receive a CT 
scan of the head, and 
ischaemic strokes will 
be treated subsequently 
with antiplatelet or 
anticoagulant therapy 
as appropriate. 
Criteria for an urgent CT scan: 
x Patient with evolving, 
unstable signs 
x Patient already on 
antiplatelet, anticoagulant or 
thrombolytic therapy at the 
time of his/her stroke 
x Patient known to be 
suffering from a bleeding 
disorder 
x Patient with suspected 
cerebellar stroke 
x Patient with suspected SAH 
 
Criteria for a CT scan within 2 
weeks: 
x Patient being considered for 
treatment with antiplatelet, 
anticoagulant or 
thrombolytic therapy 
x Patient with uncertain 
diagnosis of stroke 
x Patient being considered for 
carotid endarterectomy 
 
Indications for not scanning: 
x Patients for whom 
antiplatelet and 
anticoagulant therapy are 
contraindicated 
x Patient is moribund 
 
Incidence of acute 
stroke = 240 per 
100,000 pop. pa. A 
high, but variable, 
proportion of these will 
meet the agreed 
criteria. 
 
The additional cost of 
the programme will vary 
widely between districts 
depending on the 
proportion of acute 
strokes currently 
admitted to hospital, 
and the proportion of 
those admitted who 
currently receive a CT 
scan. 
1. Reduced hospital 
admissions for MI and 
stroke. 
 
2. Reduced use of 
primary and community 
health services for the 
acute management and 
rehabilitation of MIs and 
strokes. 
1. Adherence to 
guidelines. 
 
2. Mortality in the 3 
years following an 
acute stroke. 
 
3. Hospital admissions 
for MI and stroke in the 
3 years following an 
acute stroke. 
 
4. Appropriate use of 
antiplatelet and 
anticoagulant therapy 
following an acute 
stroke. 
 
5. Development of a 
stroke register for 
audit/research activity. 
Compared to a policy of 
clinically assessing 
acute strokes and 
treating those classified 
as ischaemic with 
antiplatelet therapy: 
 
Between 14 and 18 
lives saved and 
between 48 and 52 
serious vascular events 
(non-fatal MIs and 
strokes, and vascular 
deaths) avoided per 
1,000 acute strokes 
scanned. 
Discounted cost per life 
saved of between 
£6,878 and £9,221. 
 
Discounted cost per 
serious vascular event 
avoided of between 
£2,376 and £2,615. 
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